BioAtla, Inc.
BioAtla, Inc. (BCAB): 15 pipeline candidates · ~1 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.3 months
D/E -1.23 · 0% dilution
Lead: Phase 2
15 candidates
N/A
N/A
A transparent, data-derived signal for BioAtla, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.0M
Cash
$2.0M
Quarterly Burn
$5.3M
Runway
1.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (15 candidates)
| Drug | Phase |
|---|---|
| BA3011 | Phase 2 |
| BA3021 | Phase 2 |
| ba3142 | Preclinical |
| ba3182 | Phase 1 |
| BA3182 (CAB-EpCAM x CAB-CD3) | Phase 1 |
| ba3361 | Preclinical |
| cab-nectin 4 x cab-cd3 | Preclinical |
| ENB003 | Phase 2 |
| evalstotug | Phase 2 |
| Evalstotug (BA3071) | Phase 2 |
Showing 10 of 15 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$44K
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 277,630 | $44K |
Frequently asked questions
How many drug candidates are in BioAtla, Inc.'s pipeline?
BioAtla, Inc. (BCAB) has 15 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BioAtla, Inc.'s lead drug candidate?
BioAtla, Inc.'s most advanced tracked candidate is BA3011 (Phase 2) for Ovarian Cancer.
What is BioAtla, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BioAtla, Inc. has approximately 1.3 months of cash runway.
What is BioAtla, Inc.'s market capitalization?
BioAtla, Inc.'s market capitalization is approximately $6.0M.
Who is the CEO of BioAtla, Inc.?
Dr. Jay M. Short Ph.D. is the chief executive officer of BioAtla, Inc. (BCAB).
Get the full picture on BioAtla, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.